Cargando…

Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing

BACKGROUND: There is a pressing need for improved methods to identify effective therapeutics for diseases. Many computational approaches have been developed to repurpose existing drugs to meet this need. However, these tools often output long lists of candidate drugs that are difficult to interpret,...

Descripción completa

Detalles Bibliográficos
Autores principales: Garana, Belinda B., Joly, James H., Delfarah, Alireza, Hong, Hyunjun, Graham, Nicholas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207828/
https://www.ncbi.nlm.nih.gov/pubmed/37226094
http://dx.doi.org/10.1186/s12859-023-05343-8
_version_ 1785046539782062080
author Garana, Belinda B.
Joly, James H.
Delfarah, Alireza
Hong, Hyunjun
Graham, Nicholas A.
author_facet Garana, Belinda B.
Joly, James H.
Delfarah, Alireza
Hong, Hyunjun
Graham, Nicholas A.
author_sort Garana, Belinda B.
collection PubMed
description BACKGROUND: There is a pressing need for improved methods to identify effective therapeutics for diseases. Many computational approaches have been developed to repurpose existing drugs to meet this need. However, these tools often output long lists of candidate drugs that are difficult to interpret, and individual drug candidates may suffer from unknown off-target effects. We reasoned that an approach which aggregates information from multiple drugs that share a common mechanism of action (MOA) would increase on-target signal compared to evaluating drugs on an individual basis. In this study, we present drug mechanism enrichment analysis (DMEA), an adaptation of gene set enrichment analysis (GSEA), which groups drugs with shared MOAs to improve the prioritization of drug repurposing candidates. RESULTS: First, we tested DMEA on simulated data and showed that it can sensitively and robustly identify an enriched drug MOA. Next, we used DMEA on three types of rank-ordered drug lists: (1) perturbagen signatures based on gene expression data, (2) drug sensitivity scores based on high-throughput cancer cell line screening, and (3) molecular classification scores of intrinsic and acquired drug resistance. In each case, DMEA detected the expected MOA as well as other relevant MOAs. Furthermore, the rankings of MOAs generated by DMEA were better than the original single-drug rankings in all tested data sets. Finally, in a drug discovery experiment, we identified potential senescence-inducing and senolytic drug MOAs for primary human mammary epithelial cells and then experimentally validated the senolytic effects of EGFR inhibitors. CONCLUSIONS: DMEA is a versatile bioinformatic tool that can improve the prioritization of candidates for drug repurposing. By grouping drugs with a shared MOA, DMEA increases on-target signal and reduces off-target effects compared to analysis of individual drugs. DMEA is publicly available as both a web application and an R package at https://belindabgarana.github.io/DMEA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12859-023-05343-8.
format Online
Article
Text
id pubmed-10207828
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102078282023-05-25 Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing Garana, Belinda B. Joly, James H. Delfarah, Alireza Hong, Hyunjun Graham, Nicholas A. BMC Bioinformatics Research BACKGROUND: There is a pressing need for improved methods to identify effective therapeutics for diseases. Many computational approaches have been developed to repurpose existing drugs to meet this need. However, these tools often output long lists of candidate drugs that are difficult to interpret, and individual drug candidates may suffer from unknown off-target effects. We reasoned that an approach which aggregates information from multiple drugs that share a common mechanism of action (MOA) would increase on-target signal compared to evaluating drugs on an individual basis. In this study, we present drug mechanism enrichment analysis (DMEA), an adaptation of gene set enrichment analysis (GSEA), which groups drugs with shared MOAs to improve the prioritization of drug repurposing candidates. RESULTS: First, we tested DMEA on simulated data and showed that it can sensitively and robustly identify an enriched drug MOA. Next, we used DMEA on three types of rank-ordered drug lists: (1) perturbagen signatures based on gene expression data, (2) drug sensitivity scores based on high-throughput cancer cell line screening, and (3) molecular classification scores of intrinsic and acquired drug resistance. In each case, DMEA detected the expected MOA as well as other relevant MOAs. Furthermore, the rankings of MOAs generated by DMEA were better than the original single-drug rankings in all tested data sets. Finally, in a drug discovery experiment, we identified potential senescence-inducing and senolytic drug MOAs for primary human mammary epithelial cells and then experimentally validated the senolytic effects of EGFR inhibitors. CONCLUSIONS: DMEA is a versatile bioinformatic tool that can improve the prioritization of candidates for drug repurposing. By grouping drugs with a shared MOA, DMEA increases on-target signal and reduces off-target effects compared to analysis of individual drugs. DMEA is publicly available as both a web application and an R package at https://belindabgarana.github.io/DMEA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12859-023-05343-8. BioMed Central 2023-05-24 /pmc/articles/PMC10207828/ /pubmed/37226094 http://dx.doi.org/10.1186/s12859-023-05343-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Garana, Belinda B.
Joly, James H.
Delfarah, Alireza
Hong, Hyunjun
Graham, Nicholas A.
Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing
title Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing
title_full Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing
title_fullStr Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing
title_full_unstemmed Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing
title_short Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing
title_sort drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207828/
https://www.ncbi.nlm.nih.gov/pubmed/37226094
http://dx.doi.org/10.1186/s12859-023-05343-8
work_keys_str_mv AT garanabelindab drugmechanismenrichmentanalysisimprovesprioritizationoftherapeuticsforrepurposing
AT jolyjamesh drugmechanismenrichmentanalysisimprovesprioritizationoftherapeuticsforrepurposing
AT delfarahalireza drugmechanismenrichmentanalysisimprovesprioritizationoftherapeuticsforrepurposing
AT honghyunjun drugmechanismenrichmentanalysisimprovesprioritizationoftherapeuticsforrepurposing
AT grahamnicholasa drugmechanismenrichmentanalysisimprovesprioritizationoftherapeuticsforrepurposing